intismeran autogene (intismeran; V940 or mRNA-4157) with KEYTRUDA (pembrolizumab) - (INTerpath-001)

September 21, 2026: Moderna, Inc. (NASDAQ: MRNA) said three ESMO Congress 2026 abstracts on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy co-developed with Merck/MSD, were accepted for presentation.

For melanoma, Phase 3 INTerpath-001 evaluating intismeran autogene plus pembrolizumab versus pembrolizumab alone in the adjuvant treatment of resected stage IIB-IV melanoma was selected for a Presidential Symposium (LBA1) on October 24, 2026.

For pancreatic cancer, a Phase 1 study of adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma will be presented as poster abstract 3151P on October 25, 2026.

For lung cancer, poster abstract 2550TiP outlines the Phase 3 INTerpath-014 trial of adjuvant intismeran autogene plus subcutaneous pembrolizumab, or intismeran monotherapy, versus placebo in completely resected high-risk stage I NSCLC; it will be presented October 26, 2026.

Moderna also plans an investor webcast on October 24, 2026, at 7:00 PM CEST / 1:00 PM EDT.